Related Experiment Video
Updated: May 18, 2026
11:16
A Novel Procedure for Evaluating the Reinforcing Properties of Tastants in Laboratory Rats: Operant Intraoral Self-administration
Published on: February 6, 2014
Sugar-free medicines are counterproductive
1Department of Oncology, Nottingham University Hospitals NHS trust, Hucknall road, Nottingham, UK. santhanam.sundar@nuh.nhs.uk
British Dental Journal
|September 8, 2012
Summary
Sugar in medicines poses minimal dental risk, especially compared to high sugar intake from other foods. Promoting sugar-free medicines may negatively impact treatment compliance and overall health outcomes.
Area of Science:
- Public Health
- Pediatrics
- Pharmacology
Background:
- Dental caries is a significant public health issue, often linked to dietary sugar intake.
- Concerns exist regarding the sugar content in pediatric medications and its potential contribution to dental problems.
- Current public health initiatives promote sugar-free medicines, but their overall impact requires scrutiny.
Purpose of the Study:
- To evaluate the dental health implications of sugar in medicines versus dietary sugar.
- To assess the impact of sugar-free medicine policies on patient compliance and health outcomes.
- To question the net benefit of promoting sugar-free medicines in light of children's high dietary sugar consumption.
Main Methods:
- Literature review on sugar's role in dental health.
- Analysis of a British Heart Foundation survey on children's dietary habits.
- Assessment of the relationship between medicine palatability, compliance, and treatment efficacy.
Main Results:
- No evidence links the small amount of sugar in medicines to dental problems.
- A significant proportion of UK children consume high levels of sugar from sweets, chocolate, and crisps.
- Sugar in medicines enhances palatability, improving compliance, while sugar-free alternatives may lead to poor adherence.
Conclusions:
- The dental risk from sugar in medicines is negligible compared to dietary intake.
- Promoting sugar-free medicines may inadvertently harm public health by reducing treatment compliance.
- A re-evaluation of sugar-free medicine policies is urgently needed to ensure net health benefits.
More Related Videos
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...